Upgrade to SI Premium - Free Trial

Cullinan Therapeutics (CGEM)

17.47 +0.04 (0.23%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/6/26)

Latest Headlines

Cullinan Therapeutics to advance CLN-049 to Phase 2 AML study July 28, 2026 7:00 AM - StreetInsider Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML July 28, 2026 7:00 AM - StreetInsider Form 4 Cullinan Therapeutics, For: Jul 06 Filed by: Michaelson Jennifer July 7, 2026 5:00 PM - SEC Filing Form 4 Cullinan Therapeutics, For: Jun 30 Filed by: SUMER JACQUELYN L July 2, 2026 5:01 PM - SEC Filing Form 4 Cullinan Therapeutics, For: Jun 30 Filed by: Fenton Mary Kay July 2, 2026 5:01 PM - SEC Filing Form 4 Cullinan Therapeutics, For: Jun 16 Filed by: Rosenberg Anthony June 18, 2026 5:01 PM - SEC Filing Form 4 Cullinan Therapeutics, For: Jun 16 Filed by: Meek David D. June 18, 2026 5:01 PM - SEC Filing Form 4 Cullinan Therapeutics, For: Jun 16 Filed by: Allen Andrew R June 18, 2026 5:01 PM - SEC Filing Form 4 Cullinan Therapeutics, For: Jun 16 Filed by: Webster Stephen W June 18, 2026 5:00 PM - SEC Filing Form 4 Cullinan Therapeutics, For: Jun 16 Filed by: Thistle Mary June 18, 2026 5:00 PM - SEC Filing Form 4 Cullinan Therapeutics, For: Jun 16 Filed by: Doyle Mittie June 18, 2026 5:00 PM - SEC Filing William Blair on Cullinan Oncology Inc. (CGEM): 'We continue to see multiple opportunities for upside to Cullinan shares' June 10, 2026 4:14 PM - StreetInsider Cullinan Oncology Inc. (CGEM) PT Raised to $46 at Clear Street June 10, 2026 4:10 PM - StreetInsider Cullinan Therapeutics reports clinical trial data for autoimmune treatments June 10, 2026 7:30 AM - StreetInsider Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases June 10, 2026 7:30 AM - StreetInsider Cullinan Therapeutics reports positive CLN-978 data at EULAR 2026 June 6, 2026 6:33 AM - StreetInsider Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress June 6, 2026 5:15 AM - StreetInsider Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager May 26, 2026 7:00 AM - StreetInsider Cullinan Therapeutics receives FDA orphan drug status for leukemia drug May 19, 2026 7:01 AM - StreetInsider Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia May 19, 2026 7:00 AM - StreetInsider Cullinan Oncology (CGEM) Reiterated at Buy by Stifel on CLN-978 Data May 19, 2026 6:51 AM - StreetInsider Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress May 18, 2026 5:00 PM - Globe NewsWire The Biology Came First. May 18, 2026 8:34 AM - BizWire Cullinan Oncology, Inc. (CGEM) Tops Q1 EPS by 8c May 7, 2026 7:10 AM - StreetInsider Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results May 7, 2026 7:00 AM - Globe NewsWire Form 4 Cullinan Therapeutics, For: May 05 Filed by: Michaelson Jennifer May 6, 2026 5:01 PM - SEC Filing Full Article List